Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perflutren - Molecular Biosystems

Drug Profile

Perflutren - Molecular Biosystems

Alternative Names: FS-069; Octafluoropropane; Optison; Perfluoropropane

Latest Information Update: 10 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Biosystems
  • Developer Chugai Pharmaceutical; GE Healthcare; Molecular Biosystems; OncoGenex Pharmaceuticals
  • Class Contrast media; Fluorocarbons
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Left ventricular dysfunction

Most Recent Events

  • 25 Jun 2009 CHMP of the EMEA recommends the lifting of the suspension of the marketing authorisation for Perflutren in the European Union
  • 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals
  • 22 Apr 2005 Discontinued - Phase-II/III for Left ventricular dysfunction (diagnosis) in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top